Trial Profile

A Phase 2a Proof-of-Concept Study of R-107 for the Treatment of Refractory Major Depressive Disorder

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ketamine (Primary)
Indications Major depressive disorder
Focus Proof of concept; Therapeutic Use
Acronyms BEDROC
Sponsors Douglas Pharmaceuticals

Most Recent Events

03 Apr 2025 Results published in the Tasman Therapeutics Media Release.
01 Jul 2024 Results assessing safety efficacy and tolerability of (R-107), compared with other routes of administration were published in the Nature Medicine.
24 Jun 2024 According to Douglas Pharmaceuticals media release, data from the study were presented by the leading scientific journal Nature Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com